Merck Sharp & Dohme LLC: clinical-trial pipeline
Merck Sharp & Dohme LLC is the sponsor of 2,187 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 235 are not yet finished and 19 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials235
Phase 2/3 and 3742
Countries67
New in 90 days19
Trials by phase
| Phase | Trials |
|---|---|
| Phase 3 | 713 |
| Phase 1 | 675 |
| Phase 2 | 459 |
| Not applicable | 148 |
| Phase 4 | 93 |
| Phase 1/2 | 69 |
| Phase 2/3 | 29 |
| Early phase 1 | 1 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 1,620 |
| Terminated | 282 |
| Recruiting | 120 |
| Active, not recruiting | 93 |
| Withdrawn or not authorised | 46 |
| Not yet recruiting | 22 |
| Unknown | 3 |
| Suspended or halted | 1 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 568 |
| Infectious disease and vaccines | 565 |
| Gastroenterology and liver | 282 |
| Neurology | 279 |
| Metabolic and endocrine (diabetes, obesity) | 228 |
| Cardiovascular | 146 |
| Nephrology and urology | 121 |
| Immunology and rheumatology | 118 |
| Respiratory | 83 |
| Rare and genetic diseases | 73 |
| Women's health and obstetrics | 68 |
| Psychiatry and mental health | 57 |
Countries
| Country | Trials |
|---|---|
| United States | 581 |
| Spain | 272 |
| Canada | 235 |
| France | 235 |
| South Korea | 223 |
| Italy | 222 |
| Israel | 220 |
| Germany | 213 |
| Australia | 209 |
| United Kingdom | 207 |
| Japan | 199 |
| Poland | 199 |
| Chile | 180 |
| Taiwan | 160 |
| China | 153 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-10-23 | New trial posted | A clinical trial of MK-7228 in healthy participants (MK-7228-003) |
| 2026-10-15 | New trial posted | A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) |
| 2026-10-15 | New trial posted | Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease… |
| 2026-10-13 | New trial posted | A Clinical Trial of MK-6255 to Treat Endometrial and Ovarian Cancer (MK-6255-001) |
| 2026-10-09 | New trial posted | A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK… |
| 2026-10-07 | New trial posted | A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-69… |
| 2026-10-07 | New trial posted | DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg |
| 2026-10-07 | New trial posted | A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6… |
| 2026-10-06 | New trial posted | A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-… |
| 2026-10-02 | New trial posted | A Clinical Trial of V175 and V175A in Healthy Adults |
| 2026-09-30 | New trial posted | A clinical trial of MK-3586 in healthy participants (MK-3586-001) |
| 2026-09-30 | New trial posted | A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Indiv… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT06307431 | A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). | Phase 2 | Active, not recruiting | Argentina, Australia, Canada, Chile +9 |
| NCT06136650 | A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castra… | Phase 3 | Recruiting | Australia, Brazil, Canada, Chile +34 |
| NCT06136624 | Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | Recruiting | Argentina, Austria, Australia, Brazil +31 |
| NCT04586231 | A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cel… | Phase 3 | Active, not recruiting | Argentina, Austria, Australia, Belgium +21 |
| NCT06079879 | A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essen… | Phase 3 | Active, not recruiting | Argentina, Australia, Belgium, Canada +19 |
| NCT06077760 | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Parti… | Phase 3 | Recruiting | Argentina, Australia, Belgium, Brazil +29 |
| NCT05705349 | DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053) | Phase 3 | Active, not recruiting | Argentina, Canada, Switzerland, Chile +16 |
| NCT04938817 | Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3… | Phase 1/2 | Active, not recruiting | Austria, Australia, Canada, Switzerland +8 |
| NCT06305767 | A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V94… | Phase 1/2 | Active, not recruiting | Australia, Canada, Chile, Colombia +11 |
| NCT04665037 | Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-12… | Phase 2 | Recruiting | Belgium, Greece, Israel, South Korea +6 |
| NCT02861573 | Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK… | Phase 1/2 | Active, not recruiting | Austria, Germany, Denmark, Spain +7 |
| NCT06395103 | Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or… | Phase 1/2 | Recruiting | Australia, Belgium, Brazil, Canada +18 |
| NCT06351631 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | Phase 3 | Recruiting | Australia, United Kingdom, Hong Kong SAR China, Italy +2 |
| NCT06312176 | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475… | Phase 3 | Recruiting | Argentina, Australia, Belgium, Brazil +36 |
| NCT06312137 | A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in… | Phase 3 | Recruiting | Argentina, Austria, Australia, Belgium +26 |
| 2023-508683-30-00 | A Registry-Based Extension of Protocol V503-001 in Countries with Centralized Cervical Cancer Screening Infra… | Phase 3 | Active, not recruiting | Denmark, Norway, Sweden |
| NCT06356311 | A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma… | Phase 3 | Active, not recruiting | Belgium, Brazil, Canada, Chile +19 |
| 2022-502781-24-01 | A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Red… | Phase 3 | Active, not recruiting | Germany, Denmark, Spain, France +5 |
| NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Phase 3 | Recruiting | Argentina, Austria, Australia, Belgium +26 |
| NCT06345729 | A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small… | Phase 3 | Recruiting | Argentina, Austria, Australia, Bulgaria +25 |
| 2022-501697-19-01 | A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or… | Phase 3 | Recruiting | Belgium, Czechia, Germany, Denmark +6 |
| NCT06305754 | Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With… | Phase 3 | Active, not recruiting | Argentina, Canada, China, Colombia +14 |
| NCT05562830 | A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advance… | Phase 1/2 | Recruiting | Australia, Canada, Chile, Denmark +7 |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advan… | Phase 1/2 | Recruiting | Brazil, Switzerland, Chile, China +9 |
| NCT05468697 | A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants… | Phase 1/2 | Active, not recruiting | Australia, Germany, Spain, France +5 |
Website: msd.com. All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "Merck Sharp & Dohme LLC clinical trials: 235 open, 742 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/msd-com/, data as of 2026-10-25.